JP2023509968A5 - - Google Patents
Info
- Publication number
- JP2023509968A5 JP2023509968A5 JP2022542216A JP2022542216A JP2023509968A5 JP 2023509968 A5 JP2023509968 A5 JP 2023509968A5 JP 2022542216 A JP2022542216 A JP 2022542216A JP 2022542216 A JP2022542216 A JP 2022542216A JP 2023509968 A5 JP2023509968 A5 JP 2023509968A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- human subject
- inhibitor
- malignant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025186533A JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| US62/958,632 | 2020-01-08 | ||
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186533A Division JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023509968A JP2023509968A (ja) | 2023-03-10 |
| JP2023509968A5 true JP2023509968A5 (https=) | 2024-01-17 |
| JP7771064B2 JP7771064B2 (ja) | 2025-11-17 |
Family
ID=76788747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542216A Active JP7771064B2 (ja) | 2020-01-08 | 2021-01-08 | 脾腫を治療する方法 |
| JP2025186533A Pending JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025186533A Pending JP2026027353A (ja) | 2020-01-08 | 2025-11-05 | 脾腫を治療する方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3980069A4 (https=) |
| JP (2) | JP7771064B2 (https=) |
| KR (1) | KR20220130151A (https=) |
| CN (1) | CN114423457A (https=) |
| AU (1) | AU2021205484A1 (https=) |
| BR (1) | BR112022013646A2 (https=) |
| CA (1) | CA3164063A1 (https=) |
| CO (1) | CO2022010592A2 (https=) |
| CR (1) | CR20220374A (https=) |
| IL (1) | IL294582A (https=) |
| JO (1) | JOP20220168A1 (https=) |
| MA (3) | MA57226B1 (https=) |
| MX (1) | MX2022008490A (https=) |
| TN (1) | TN2022000185A1 (https=) |
| WO (1) | WO2021142257A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| TN2022000185A1 (en) * | 2020-01-08 | 2024-04-01 | Telios Pharma Inc | Methods of treating splenomegaly |
| US20240293403A1 (en) * | 2021-06-16 | 2024-09-05 | Telios Pharma, Inc. | Treatment of Symptoms Associated with Myeloproliferative Neoplasms |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| WO2024041614A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene Switzerland Gmbh | Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112020025881A2 (pt) * | 2018-06-19 | 2021-03-23 | Merck Patent Gmbh | formas cristalinas de 1-(4-{[6-amino-5-(4-fenóxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal do mesmo e processos para obter as mesmas |
| CN109942835A (zh) * | 2019-03-27 | 2019-06-28 | 广州楹鼎生物科技有限公司 | 一种催化分解木质纤维原料的方法 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| TN2022000185A1 (en) * | 2020-01-08 | 2024-04-01 | Telios Pharma Inc | Methods of treating splenomegaly |
-
2021
- 2021-01-08 TN TNP/2022/000185A patent/TN2022000185A1/en unknown
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 MA MA63848A patent/MA63848B1/fr unknown
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en not_active Ceased
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MA MA69153A patent/MA69153A1/fr unknown
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko active Pending
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 JP JP2022542216A patent/JP7771064B2/ja active Active
-
2022
- 2022-07-07 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
-
2025
- 2025-11-05 JP JP2025186533A patent/JP2026027353A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509968A5 (https=) | ||
| IL294582A (en) | Methods for treating an enlarged spleen | |
| JP6364546B2 (ja) | 抗腫瘍剤の副作用軽減剤 | |
| CN1350454A (zh) | 阿朴吗啡和西地拉非组合物 | |
| US20080032989A1 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| JPH02240021A (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| JP2021523220A5 (https=) | ||
| EA037152B1 (ru) | Способ лечения рака | |
| US12544370B2 (en) | Methods for cancer therapy | |
| CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
| CN114681455A (zh) | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 | |
| JP2025507830A5 (https=) | ||
| TW202011948A (zh) | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| RU2003332C1 (ru) | Средство дл лечени депрессий | |
| JP2002539247A (ja) | マンズアミンの抗炎症作用の使用 | |
| BR112020016389A2 (pt) | Uso de 5-fluor-4-(4-fluor-2-metoxifenil)-n-{4-[(s-metilsulfonimidoil)metil]piridin-2-il}piridin-2-amina para tratamento de linfoma difuso de células b grandes | |
| EP4225316A1 (en) | Use of an erk inhibitor for the treatment of myelofibrosis | |
| CN115177622A (zh) | 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用 | |
| RU2519199C2 (ru) | Противоопухолевый агент, набор и способ лечения рака | |
| CN113274394A (zh) | 一种治疗酪氨酸激酶抑制剂耐药的非小细胞肺癌的药物组合物 | |
| WO2022074600A1 (en) | Use of an erk inhibitor for the treatment of myelofibrosis | |
| MXPA06014477A (es) | Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer. | |
| US20250381190A1 (en) | Therapeutic combinations of capivasertib and venetoclax | |
| Gajdosik | Upadacitinib tartrate. Tyrosine-protein kinase JAK1 inhibitor, Treatment of autoimmune inflammatory diseases, Treatment of rheumatoid arthritis |